{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T18:40:11Z","timestamp":1756579211713,"version":"3.44.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Daratumumab is an anti-CD38 mAb, used frequently in combination with lenalidomide and pomalidomide. No studies compared daratumumab plus lenalidomide and dexamethasone (DRd) to daratumumab plus pomalidomide and dexamethasone (DPd) in lenalidomide-exposed multiple myeloma. We identified 504 consecutive multiple myeloma patients who received daratumumab at Mayo Clinic between January 2015 and April 2019. We excluded patients who received daratumumab in the first line, received more than four lines of therapy prior to daratumumab use, did not receive lenalidomide prior to daratumumab, or had an unknown status of lenalidomide exposure, and patients who received daratumumab combinations other than DRd or DPd. We examined the impact of using DRd compared to DPd on progression-free survival (PFS) and overall survival (OS) in patients with relapsed\/refractory multiple myeloma. Out of 504 patients, 162 received DRd or DPd and were included; 67 were lenalidomide-exposed and 95 were lenalidomide-refractory. DRd was used in 76 (47%) and DPd in 86 (53%) patients. In lenalidomide-exposed multiple myeloma, there was no difference in median PFS; 34.2\u2005months [95% confidence interval (CI), 22.8\u201344.6] for DRd compared to 25.2\u2005months (95% CI, 4.9\u201335.3) for DPd, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.2. In lenalidomide-refractory multiple myeloma, there was no difference in median PFS; 18.6\u2005months (95% CI, 13\u201332) for DRd compared to 9\u2005months (95% CI, 5.2\u201314.6) for DPd, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.09. No difference in median OS was observed in DRd compared to DPd. Our study shows combining daratumumab with lenalidomide in patients with prior lenalidomide use is a viable and effective treatment option.<\/jats:p>","DOI":"10.1097\/cad.0000000000001520","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T13:19:40Z","timestamp":1681737580000},"page":"63-69","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma"],"prefix":"10.1097","volume":"35","author":[{"given":"Muhamad","family":"Alhaj Moustafa","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Parrondo","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mays F.","family":"Abdulazeez","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taimur","family":"Sher","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria R.","family":"Alegria","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahma M.","family":"Warsame","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahsan","family":"Rasheed","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig B.","family":"Reeder","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asher A.","family":"Chanan-Khan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"R1-20250830","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma.","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"R2-20250830","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms.","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"key":"R3-20250830","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/hematology.2020000109","article-title":"Sequencing multiple myeloma therapies with and after antibody therapies.","volume":"2020","author":"van de Donk","year":"2020","journal-title":"Hematology"},{"key":"R4-20250830","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"R5-20250830","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma.","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"R6-20250830","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"key":"R7-20250830","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma.","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"R8-20250830","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"R9-20250830","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"R10-20250830","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"R11-20250830","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/s41375-020-0813-1","article-title":"Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.","volume":"34","author":"Siegel","year":"2020","journal-title":"Leukemia"},{"key":"R12-20250830","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma.","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"R13-20250830","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"R14-20250830","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma.","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"R15-20250830","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma.","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"R16-20250830","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","article-title":"Clinically relevant end points and new drug approvals for myeloma.","volume":"22","author":"Anderson","year":"2008","journal-title":"Leukemia"},{"key":"R17-20250830","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1002\/cncr.32177","article-title":"Recycling therapies for myeloma: the need for prospective trials.","volume":"125","author":"Kumar","year":"2019","journal-title":"Cancer"},{"key":"R18-20250830","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.clml.2017.12.011","article-title":"A comparison of the efficacy of immunomodulatory-containing regimens in relapsed\/refractory multiple myeloma: a network meta-analysis.","volume":"18","author":"Dimopoulos","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R19-20250830","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"R20-20250830","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"key":"R21-20250830","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.15504","article-title":"Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.","volume":"183","author":"Oostvogels","year":"2018","journal-title":"Br J Haematol"},{"key":"R22-20250830","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2017-10-809293","article-title":"The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.","volume":"131","author":"Gavriatopoulou","year":"2018","journal-title":"Blood"},{"key":"R23-20250830","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"R24-20250830","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.clml.2019.04.003","article-title":"Pomalidomide-based regimens for treatment of relapsed and relapsed\/refractory multiple myeloma: systematic review and meta-analysis of phase 2 and 3 clinical trials.","volume":"19","author":"Mushtaq","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0000000000001520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T18:02:55Z","timestamp":1756576975000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0000000000001520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0000000000001520","relation":{},"ISSN":["0959-4973"],"issn-type":[{"type":"print","value":"0959-4973"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}